SCHEMBL3698746

SCHEMBL3698746

CC(NC(=O)c1cn2cc(-c3ccco3)cc(C(F)(F)F)c2n1)c1cccs1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.40
KDM4E B2RXH2 4/20 0.40
HPGD P15428 3/20 0.40
POLB P06746 2/20 0.39
MAPT P10636 1/20 0.39
NPC1 O15118 2/20 0.38
RAB9A P51151 2/20 0.38
TSHR P16473 1/20 0.38
CYP1A2 P05177 1/20 0.36
CYP2C8 P10632 1/20 0.36
CYP2D6 P10635 1/20 0.36
CYP2C9 P11712 1/20 0.36
CYP2B6 P20813 1/20 0.36
CYP2C19 P33261 1/20 0.36
MEN1 O00255 2/20 0.35
KMT2A Q03164 2/20 0.35
SMN1; SMN2 Q16637 3/20 0.34
LMNA P02545 2/20 0.34
ALOX15 P16050 2/20 0.34
NPSR1 Q6W5P4 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7495089 0.83 KDM4E (0.42) ALDH1A1KDM4EHPGDPOLBMAPT
SCHEMBL7486958 0.82 HTT (0.47) ALDH1A1KDM4EHPGDPOLBMAPT
SCHEMBL3704069 0.79 ADORA2A (0.46) ALDH1A1KDM4EHPGDPOLBMAPT
SCHEMBL3698748 0.77 ALDH1A1 (0.40) ALDH1A1KDM4EHPGDMAPTNPC1
SCHEMBL3690516 0.72 KDM4E (0.38) ALDH1A1KDM4EHPGDPOLBMAPT
SCHEMBL3690130 0.72 TACR3 (0.40) ALDH1A1KDM4EHPGDPOLBMAPT
SCHEMBL3694041 0.69 ALDH1A1 (0.38) ALDH1A1KDM4EHPGDPOLBMAPT
SCHEMBL23381612 0.69 ALDH1A1 (0.39) ALDH1A1KDM4EHPGDPOLBMAPT
SCHEMBL3691623 0.69 ADORA3 (0.42) ALDH1A1KDM4EHPGDPOLBMEN1
SCHEMBL3786086 0.69 EGLN1 (0.38) ALDH1A1KDM4EMEN1KMT2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120121540-A1 Certain Nitrogen Containing Bicyclic Chemical Entities For Treating Viral Infections GLAXOSMITHKLINE LLC 2012-05-17 US disclosed
EP-2187883-A2 NITROGEN CONTAINING BICYCLIC CHEMICAL ENTITIES FOR TREATING VIRAL INFECTIONS GENELABS TECHNOLOGIES, INC. (US) 2010-05-26 EP disclosed
US-20090176778-A1 Certain nitrogen containing bicyclic chemical entities for treating viral infections GLAXOSMITHKLINE LLC 2009-07-09 US disclosed
WO-2009023179-A2 NITROGEN CONTAINING BICYCLIC CHEMICAL ENTITIES FOR TREATING VIRAL INFECTIONS GENELABS TECHNOLOGIES, INC. (US) 2009-02-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120121540-A1 Certain Nitrogen Containing Bicyclic Chemical Entities For Treating Viral Infections OAT, HAVCR2, CPS1 ALDH1A1 1337/4885KDM4E 2131/4885HPGD 446/4885
US-20090176778-A1 Certain nitrogen containing bicyclic chemical entities for treating viral infections OAT, HAVCR2, CPS1 ALDH1A1 1337/4885KDM4E 2131/4885HPGD 446/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.